Pub Date : 2025-12-17DOI: 10.1016/j.ad.2025.104564
K.M. Ramirez-Gomez , A. Imbernon-Moya , M.F. Villegas-Calzada , S. Vano-Galvan , D. Saceda-Corralo
Graying is a natural process, characterized by the loss of pigment in the hair, and is considered a sign of aging in society; its onset and progression is closely correlated with age and occurs to varying degrees in all individuals, regardless of gender or race. However, premature graying has a psychological and social impact, affecting patients’ self-esteem. The exact etiopathogenesis is still unknown, and it has been associated with multiple factors such as: oxidative stress, ultraviolet radiation, genetic factors, and lifestyle factors such as smoking, nutritional and emotional factors. All of this causes a decrease in the production of melanin by the melanocytes of the hair bulb. Despite the extensive molecular research being carried out to understand the pathogenesis of graying, there is a shortage of effective, evidence-based treatment options. Today, graying has become a cultural phenomenon, where many people opt for cosmetic treatments to cover gray hair.
{"title":"Hair Graying Update and Review","authors":"K.M. Ramirez-Gomez , A. Imbernon-Moya , M.F. Villegas-Calzada , S. Vano-Galvan , D. Saceda-Corralo","doi":"10.1016/j.ad.2025.104564","DOIUrl":"10.1016/j.ad.2025.104564","url":null,"abstract":"<div><div>Graying is a natural process, characterized by the loss of pigment in the hair, and is considered a sign of aging in society; its onset and progression is closely correlated with age and occurs to varying degrees in all individuals, regardless of gender or race. However, premature graying has a psychological and social impact, affecting patients’ self-esteem. The exact etiopathogenesis is still unknown, and it has been associated with multiple factors such as: oxidative stress, ultraviolet radiation, genetic factors, and lifestyle factors such as smoking, nutritional and emotional factors. All of this causes a decrease in the production of melanin by the melanocytes of the hair bulb. Despite the extensive molecular research being carried out to understand the pathogenesis of graying, there is a shortage of effective, evidence-based treatment options. Today, graying has become a cultural phenomenon, where many people opt for cosmetic treatments to cover gray hair.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104564"},"PeriodicalIF":2.8,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Artificial intelligence (AI) has evolved from science fiction into a key tool in everyday life. In cosmetic dermatology, it has revolutionized skin assessment and the development of personalized treatments. Advanced algorithms enable the diagnosis of conditions, predict responses to laser therapies, and optimize dermocosmetic formulations. Mobile applications such as Skiana® and PROVEN Beauty® analyze the skin and recommend products, while clinical devices like VISIA® facilitate diagnosis. Machine learning and deep learning models enhance accuracy in detecting dermatological issues but still face challenges such as data biases and clinical validation. As AI advances, it promises to transform cosmetic dermatology with more efficient and personalized approaches.
{"title":"Advances in Artificial Intelligence in Cosmetic Dermatology","authors":"D.E. Pimienta-Rosero , E.Y. Benavides-Tulcán , D.C. Fajardo-Murcia","doi":"10.1016/j.ad.2025.104560","DOIUrl":"10.1016/j.ad.2025.104560","url":null,"abstract":"<div><div>Artificial intelligence (AI) has evolved from science fiction into a key tool in everyday life. In cosmetic dermatology, it has revolutionized skin assessment and the development of personalized treatments. Advanced algorithms enable the diagnosis of conditions, predict responses to laser therapies, and optimize dermocosmetic formulations. Mobile applications such as Skiana® and PROVEN Beauty® analyze the skin and recommend products, while clinical devices like VISIA® facilitate diagnosis. Machine learning and deep learning models enhance accuracy in detecting dermatological issues but still face challenges such as data biases and clinical validation. As AI advances, it promises to transform cosmetic dermatology with more efficient and personalized approaches.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 4","pages":"Article 104560"},"PeriodicalIF":2.8,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-17DOI: 10.1016/j.ad.2025.104572
C. Sobrino García-Yanes, C. Carrión-García, A. Garrido-Ríos, B. Echeverría-García, H. Álvarez-Garrido, J. Borbujo-Martínez
{"title":"Cutaneous Ultrasound in Digital Fibrokeratomas: Series of 4 Cases","authors":"C. Sobrino García-Yanes, C. Carrión-García, A. Garrido-Ríos, B. Echeverría-García, H. Álvarez-Garrido, J. Borbujo-Martínez","doi":"10.1016/j.ad.2025.104572","DOIUrl":"10.1016/j.ad.2025.104572","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104572"},"PeriodicalIF":2.8,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-17DOI: 10.1016/j.ad.2025.104569
C.D. Villarreal-Villarreal , E. Boland-Rodriguez , D. Mares-Custodio , D. Asz-Sigall , J.F. Molina-de la Garza , D. Saceda-Corralo , S. Vano-Galvan
Background and objective
Coronavirus disease 2019 (COVID-19) associated telogen effluvium (CATE) has been observed in patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although it is self-limiting, hair loss can be very distressing, and some patients may seek medical treatment to help promote hair regrowth. Low-dose oral minoxidil (LDOM) has emerged as a novel and very efficient therapy for different types of alopecia. However, information on its safety and efficacy profile in the management of CATE remains scarce. This study aims to evaluate the treatment response to LDOM in CATE patients.
Methods
We conducted a retrospective study at a single dermatology center. Adult patients diagnosed with telogen effluvium from December 2020 to October 2022, with a prior history of SARS-CoV-2 infection, and treated with LDOM were included. The efficacy of LDOM was evaluated with the hair-shedding score (HSS).
Results
In all, 69 patients, 50 (72.5%) women and 19 (27.5%) men were included. A total of 55 patients (79.7%) exhibited mild and moderate symptoms; 8 (11.5%), severe disease; and 6 (8.7%) remained asymptomatic. The time elapsed between COVID-19 and telogen effluvium diagnosis was 117 days (80–181). The HSS continuously decreased during the 2nd, 3rd, and 4th visits after treatment initiation. Compared with baseline, the median (interquartile range) HSS was significantly lower at the 2nd visit (5 [5–6]; P < .001), the 3rd visit (4 [3–5]; P < .001), and the 4th visit (2 [1–2]; P < .001). The time for telogen effluvium resolution was 93 days (55–148).
Conclusions
Our findings suggest that LDOM is a safe and effective therapy for patients with CATE.
{"title":"Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients","authors":"C.D. Villarreal-Villarreal , E. Boland-Rodriguez , D. Mares-Custodio , D. Asz-Sigall , J.F. Molina-de la Garza , D. Saceda-Corralo , S. Vano-Galvan","doi":"10.1016/j.ad.2025.104569","DOIUrl":"10.1016/j.ad.2025.104569","url":null,"abstract":"<div><h3>Background and objective</h3><div>Coronavirus disease 2019 (COVID-19) associated telogen effluvium (CATE) has been observed in patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although it is self-limiting, hair loss can be very distressing, and some patients may seek medical treatment to help promote hair regrowth. Low-dose oral minoxidil (LDOM) has emerged as a novel and very efficient therapy for different types of alopecia. However, information on its safety and efficacy profile in the management of CATE remains scarce. This study aims to evaluate the treatment response to LDOM in CATE patients.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study at a single dermatology center. Adult patients diagnosed with telogen effluvium from December 2020 to October 2022, with a prior history of SARS-CoV-2 infection, and treated with LDOM were included. The efficacy of LDOM was evaluated with the hair-shedding score (HSS).</div></div><div><h3>Results</h3><div>In all, 69 patients, 50 (72.5%) women and 19 (27.5%) men were included. A total of 55 patients (79.7%) exhibited mild and moderate symptoms; 8 (11.5%), severe disease; and 6 (8.7%) remained asymptomatic. The time elapsed between COVID-19 and telogen effluvium diagnosis was 117 days (80–181). The HSS continuously decreased during the 2nd, 3rd, and 4th visits after treatment initiation. Compared with baseline, the median (interquartile range) HSS was significantly lower at the 2nd visit (5 [5–6]; <em>P</em> <!--><<!--> <!-->.001), the 3rd visit (4 [3–5]; <em>P</em> <!--><<!--> <!-->.001), and the 4th visit (2 [1–2]; <em>P</em> <!--><<!--> <!-->.001). The time for telogen effluvium resolution was 93 days (55–148).</div></div><div><h3>Conclusions</h3><div>Our findings suggest that LDOM is a safe and effective therapy for patients with CATE.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 5","pages":"Article 104569"},"PeriodicalIF":2.8,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号